[4] [4] Dwyer GK, D'Cruz LM, Turnquist HR. Emerging functions of IL-33 in homeostasis and immunity[J]. Annu Rev Immunol, 2022, 40: 15-43.

[5] [5] Sun Y, Pavey H, Wilkinson I, et al. Role of the IL-33/ST2 axis in cardiovascular disease: a systematic review and meta-analysis[J]. PLoS One, 2021, 16(11): e0259026.

[6] [6] Puca AA, Carrizzo A, Spinelli C, et al. Single systemic transfer of a human gene associated with exceptional longevity halts the progression of atherosclerosis and inflammation in ApoE knockout mice through a CXCR4-mediated mechanism[J]. Eur Heart J, 2020, 41(26): 2487-2497.

[7] [7] Jiang C, Jin X, Li C, et al. Roles of IL-33 in the pathogenesis of cardiac disorders[J]. Exp Biol Med (Maywood), 2023, 248(22): 2167-2174.

[8] [8] Cazzola M, Calzetta L, Rogliani P, et al. Emerging anti-inflammatory COPD treatments: potential cardiovascular impacts[J]. Int J Chronic Obstr Pulm Dis, 2024, 19: 2481-2495.

[10] [10] Witkowska A, Staciwa M, Duraj I, et al. Interleukin-33/sST2: dynamic assessment in patients with acute coronary syndrome[J]. Adv Med Sci, 2023, 68(2): 195-201.

[12] [12] Cheng TY, Chen YC, Li SJ, et al. Interleukin-33/ST2 axis involvement in atrial remodeling and rrrhythmogenesis[J]. Transl Res, 2024, 268: 1-12.

[17] [17] Chen WY, Wu YH, Tsai TH, et al. Group 2 innate lymphoid cells contribute to IL-33-mediated alleviation of cardiac fibrosis[J]. Theranostics, 2021, 11(6): 2594-2611.

[18] [18] Li L, Zhong D, Xie Y, et al. Blood microRNA 202-3p associates with the risk of essential hypertension by targeting soluble ST2[J]. Biosci Rep, 2020, 40(5): BSR20200378.

[22] [22] De Luca M, Crisci G, Armentaro G, et al. Endothelial dysfunction and heart failure with preserved ejection fraction-an updated review of the literature[J]. Life (Basel), 2023, 14(1): 30.

[23] [23] Duan H, Zhang Q, Liu J, et al. Suppression of apoptosis in vascular endothelial cell, the promising way for natural medicines to treat atherosclerosis[J]. Pharmacol Res, 2021, 168: 105599.

[24] [24] Tembhre MK, Sriwastva MK, Hote MP, et al. Interleukin-33 induces neutrophil extracellular trap (NET) formation and macrophage necroptosis via enhancing oxidative stress and secretion of proatherogenic factors in advanced atherosclerosis[J]. Antioxidants (Basel), 2022, 11(12): 2343.

[27] [27] Ji C, Wang X, Xue B, et al. A fluorescent nano vector for early diagnosis and enhanced interleukin-33 therapy of thoracic aortic dissection[J]. Biomaterials, 2023, 293: 121958.

[29] [29] Wang X, Li F, Li Y, et al. Decreased levels of immune-regulatory cytokines in patients with immune thrombocytopenia and long-lasting overexpression of these cytokines in the splenectomized patients[J]. J Leukoc Biol, 2021, 110(2): 335-341.

[31] [31] Yang J, Huang X, Hu F, et al. LncRNA ANRIL knockdown relieves myocardial cell apoptosis in acute myocardial infarction by regulating IL-33/ST2[J]. Cell Cycle, 2019, 18(23): 3393-3403.

[32] [32] Zhao YN, Li H, Zhao C, et al. ST2 silencing aggravates ventricular remodeling and chronic heart failure in rats by mediating the IL-33/ST2 axis[J]. J Tissue Eng Regen Med, 2020, 14(9): 1201-1212.

[33] [33] Wu MX, Wang SH, Xie Y, et al. Interleukin-33 alleviates diabetic cardiomyopathy through regulation of endoplasmic reticulum stress and autophagy via insulin-like growth factor-binding protein 3[J]. J Cell Physiol, 2021, 236(6): 4403-4419.

[34] [34] Adkar SS, Leeper NJ. Efferocytosis in atherosclerosis[J]. Nat Rev Cardiol, 2024, 21(11): 762-779.

[35] [35] Shlomovitz I, Erlich Z, Speir M, et al. Necroptosis directly induces the release of full-length biologically active IL-33 in vitro and in an inflammatory disease model[J]. FEBS J, 2019, 286(3): 507-522.